Surfactant treatment of implantable biological tissue to inhibit calcification

• US 4,885,005 A
• Filed: 02/27/1987
• Issued: 12/05/1989
• Est. Priority Date: 11/12/1982
• Status: Expired due to Term

• Current Assignee: Edwards Lifesciences Corporation
• Original Assignee: Baxter International Inc.
• Inventors: Ahmed, Ahmed I., Nashef, Aws S.
• Primary Examiner(s): Lieberman, Paul
• Assistant Examiner(s): MCNALLY, JOHN
• Application Number:
  US07/020,202
• Time in Patent Office: 1,012 Days
• Field of Search: 8/94.11, 623/1, 623/2, 623/3
• US Class Current: 8/94.11
• CPC Class Codes: A61L 2400/02 Treatment of implants to prevent calcification or mineralisation in vivo
• CPC Class Codes: A61L 27/3687 characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: Y10S 623/922 Heart

Abstract

A process for the preparation of implantable biological tissue, and in particular bioprosthetic heart valves, which are prone to calcification after implantation. The process includes the treatment of tissue with an effective amount of a surfactant to reduce calcification of the implanted tissue.

Claims

1. A method for reducing calcification of soft biological tissue after implantation in an animal comprising:

chemically fixing the biological tissue under tissue fixing conditions; and

contacting the fixed biological tissue with a solution of a nonionic surfactant prior to implantation wherein the amount of surfactant in the solution is from about 0.1 to about 10 weight percent in an amount effective in reducing calcification of the tissue after implantation.

2. The method of claim 1 wherein the surfactant is selected from the group consisting of polyoxyalkylene ethers, polyoxyalkylene alkylaryl ethers, polyoxyalkylene esters, sorbitan esters, and polyoxyalkylene sorbitan esters.

3. The method of claim 1 wherein the tissue is contacted with surfactant during fixation.

4. The method of claim 1 wherein the tissue is contacted with surfactant during post-fixation sterilization.

5. The method of claim 1 wherein the tissue is contacted with the surfactant solution for a time from about 2 to about 30 hours.

6. The method of claim 1 wherein the amount of surfactant in the solution is from 0.5 to about 5 weight percent.

7. The method of claim 6 wherein the surfactant is sorbitan monooleate polyoxyethylene.

8. The method of claim 1 wherein the tissue is fixed with glutaraldehyde.

9. The method of claim 1 wherein the tissue is fixed with glutaraldehyde;

and is contacted with a solution having from about 0.1 to about 10 weight percent of surfactant selected from the group consisting of polyoxyalkylene ethers, polyoxyalkylene alkylaryl ethers, polyoxyalkylene esters, sorbitan esters, and polyoxyalkylene sorbitan esters.

10. The method of claim 1 wherein the biological tissue is tendon, ligament, heart valve, dura mater, or paricardium.

11. The method of claim 1 wherein the amount of surfactant in the solution is from about 0.1 to about 1.5 weight percent;

the biological tissue is tendon, ligament, heart valve, dura mater, or pericardium, and is fixed with glutaraldehyde;

the surfactant is sorbitan monooleate polyoxyethylene; and

the tissue is contacted with the surfactant solution for a time from about 6 to about 24 hours at a pH of from about 7.0 to about 7.6.

12. The method of claim 11 wherein the tissue is contacted with surfactant during post-fixation sterilizaton and the surfactant solution further comprises from about 4 to about 5 percent formaldehyde.